2. Academic Validation
  3. Targeting PSMD14 combined with arachidonic acid induces synthetic lethality via FADS1 m6A modification in triple-negative breast cancer

Targeting PSMD14 combined with arachidonic acid induces synthetic lethality via FADS1 m6A modification in triple-negative breast cancer

  • Sci Adv. 2025 May 9;11(19):eadr3173. doi: 10.1126/sciadv.adr3173.
Yuanhang Yu 1 2,  Jin Hu 3,  Wenwen Wang 4,  Hao Lei 5,  Zihan Xi 1,  Peiyi Zhang 2,  Ende Zhao 6,  Chong Lu 1,  Hengyu Chen 5,  Chunping Liu 1,  Lei Li 1
Affiliations

Affiliations

  • 1 Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • 2 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
  • 3 Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
  • 4 Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • 5 Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Hainan Medical University and Key Laboratory of Tropical Translational Medicine of Ministry of Education and School of Tropical Medicine, Hainan Medical University, Haikou 570311, China.
  • 6 Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
PMID: 40344056 DOI: 10.1126/sciadv.adr3173
Abstract

Dysregulation of deubiquitination is essential for Cancer growth. However, the role of 26S Proteasome non-ATPase regulatory subunit 14 (PSMD14) in the progression of triple-negative breast Cancer (TNBC) remains to be determined. Gain- and loss-of-function experiments showed that silencing PSMD14 notably attenuated the growth, invasion, and metastasis of TNBC cells in vitro and in vivo. Overexpression of PSMD14 produced the opposite results. Mechanistically, PSMD14 decreased K63-linked ubiquitination on SF3B4 protein to de-ubiquitin and stabilize SF3B4 protein. Then, SF3B4/HNRNPC complex bound to FADS1 mRNA and promoted exon inclusion in the target mRNA through m6A site on FADS1 mRNA recognized by HNRNPC, thereby up-regulating the expression of FADS1 and activating Akt/mTOR signaling. Exogenous arachidonic acid supplementation combined with PSMD14 knockdown induced synthetic lethality, which was further confirmed in TNBC Organoid (PDO) and TNBC patient-derived xenograft (PDX) mouse models. Overall, our findings reveal an oncogenic role of PSMD14 in TNBC progression, which indicates a potential biomarker and ferroptosis-mediated therapeutic strategy for TNBC.

Figures
Products